An evidence map of randomised controlled trials evaluating genetic therapies

Author:

Apaydin Eric A.ORCID,Richardson Andrea S.,Baxi Sangita,Vockley Jerry,Akinniranye Olamigoke,Ross Rachel,Larkin Jody,Motala Aneesa,Azhar Gulrez,Hempel Susanne

Abstract

ObjectivesGenetic therapies replace or inactivate disease-causing genes or introduce new or modified genes. These therapies have the potential to cure in a single application rather than treating symptoms through repeated administrations. This evidence map provides a broad overview of the genetic therapies that have been evaluated in randomised controlled trials (RCTs) for efficacy and safety.Eligibility criteriaTwo independent reviewers screened publications using predetermined eligibility criteria. Study details and data on safety and efficacy were abstracted from included trials. Results were visualised in an evidence map.Information sourcesWe searched PubMed, EMBASE, Web of Science, ClinicalTrials.gov and grey literature to November 2018.Risk of biasOnly RCTs were included in this review to reduce the risk of selection bias in the evaluation of genetic therapy safety and efficacy.Included studiesWe identified 119 RCTs evaluating genetic therapies for a variety of clinical conditions.Synthesis of resultsOn average, samples included 107 participants (range: 1–1022), and were followed for 15 months (range: 0–124). Interventions using adenoviruses (40%) to treat cardiovascular diseases (29%) were the most common.Description of the effectIn RCTs reporting safety and efficacy outcomes, in the majority (60%) genetic therapies were associated with improved symptoms but in nearly half (45%) serious adverse event (SAEs) were also reported. Improvement was reported in trials treating cancer, cardiovascular, ocular and muscular diseases. However, only 19 trials reported symptom improvement for at least 1 year.Strengths and limitations of evidenceThis is the first comprehensive evidence map of RCTs evaluating the safety and efficacy of genetic therapies. Evidence for long-term effectiveness and safety is still sparse. This lack of evidence has implications for the use, ethics, pricing and logistics of genetic therapies.InterpretationThis evidence map provides a broad overview of research studies that allow strong evidence statements regarding the safety and efficacy of genetic therapies. Most interventions improve symptoms, but SAE are also common. More research is needed to evaluate genetic therapies with regard to the potential to cure diseases.

Funder

Patient-Centered Outcomes Research Institute

Office of Academic Affiliations, Veterans Health Administration

Publisher

BMJ

Subject

General Medicine

Reference143 articles.

1. History of gene therapy

2. T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 Years

3. Gene therapy clinical trials worldwide provided by the Journal of gene medicine. indications addressed by gene therapy clinical trials. Available: http://www.abedia.com/wiley/indications.php [Accessed 30 Apr 2018].

4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research . Guidance for industry: gene therapy clinical trials – observing subjects for delayed adverse events. Rockville, MD; 2006.

5. U.S. Department of Health and Human Services, Food and Drug Administration . Approved cellular and gene therapy products, 2019. Available: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products [Accessed 07 Sep 2019].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3